BTIG Maintains MDxHealth(MDXH.US) With Buy Rating, Cuts Target Price to $6
MDxHealth Is Maintained at Overweight by Piper Sandler
MDxHealth Analyst Ratings
Lake Street Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $7
TD Cowen Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $7
Piper Sandler Maintains MDxHealth(MDXH.US) With Buy Rating, Cuts Target Price to $6
TD Cowen Maintains MDxHealth(MDXH.US) With Buy Rating, Raises Target Price to $7
MDxHealth Analyst Ratings
Lake Street Initiates MDxHealth(MDXH.US) With Buy Rating, Announces Target Price $7
BTIG Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Maintains MDxHealth(MDXH.US) With Buy Rating, Raises Target Price to $8
MDxHealth (MDXH) Receives a Buy From Piper Sandler
Strong Buy Rating for MDxHealth: Robust Revenue Growth and Strategic Value Proposition
MDxHealth (MDXH) Gets a Buy From BTIG
Analysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)
Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth Analyst Ratings
BTIG Maintains Buy on MDxHealth, Raises Price Target to $8
Buy Rating Affirmed for MDxHealth Amid Strong Q4 Performance and Positive Future Outlook
Piper Sandler Sticks to Their Buy Rating for MDxHealth S.A. Sponsored ADR (MDXH)
No Data
No Data